Bezafibrate Reduces mRNA Levels of Adipocyte Markers and Increases Fatty Acid Oxidation in Primary Culture of Adipocytes
Open Access
- 1 August 2001
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 50 (8) , 1883-1890
- https://doi.org/10.2337/diabetes.50.8.1883
Abstract
The molecular mechanisms by which peroxisome proliferator–activated receptor (PPAR) activation by fibrates reduces fat deposition and improves insulin sensitivity are not completely understood. We report that exposure of a rat primary culture of adipocytes for 24 h to the PPAR activator bezafibrate increased the mRNA levels of crucial genes involved in peroxisomal and mitochondrial β-oxidation. The mRNA levels of the peroxisomal β-oxidation rate-limiting enzyme acyl-CoA oxidase and of the muscle-type carnitine palmitoyl transferase I (M-CPT-I), which determines the flux of mitochondrial β-oxidation, increased by 1.6-fold (P < 0.02) and 4.5-fold (P = 0.001), respectively. These changes were accompanied by an increase in the transcript levels of the uncoupling protein-2 (UCP-2; 1.5-fold induction; P < 0.05) and UCP-3 (3.7-fold induction; P < 0.001), mitochondrial proteins that reduce ATP yield and may facilitate the oxidation of fatty acids. Furthermore, bezafibrate increased the mRNA levels of the fatty acid translocase (2-fold induction; P < 0.01), suggesting a higher fatty acid uptake into adipocytes. In agreement with these changes, bezafibrate caused a 1.9-fold induction (P < 0.02) in 9,10-[3H]palmitate oxidation. Moreover, bezafibrate reduced the mRNA expression of several adipocyte markers, including PPARγ (30% reduction; P = 0.05), tumor necrosis factor-α (33% reduction; P < 0.05), and the ob gene (26% reduction). In contrast, adipocyte fatty acid binding protein mRNA levels increased (1.5-fold induction; P < 0.01), pointing to a mobilization of fatty acids to mitochondria and peroxisomes. The reduction of the adipocyte markers caused by bezafibrate was accompanied by an increase in the mRNA levels of the preadipocyte marker Pref-1 (1.6-fold induction; P < 0.01). Some of the changes observed in the primary culture of rat adipocytes also were studied in the epididymal white adipose tissue of bezafibrate-treated rats for 7 days. In vivo, M-CPT-I mRNA levels increased (4.5-fold induction; P = 0.001) in epididymal white adipose tissue of bezafibrate-treated rats. Similarly, fatty acid translocase (2.6-fold induction; P = 0.002) and Pref-1 (5.6-fold induction) mRNA levels increased, although differences in the latter were not significant because of huge individual variations. These results indicate that exposure of adipocytes to bezafibrate, independent of its hepatic effects, increases the degradation of fatty acids, reducing their availability to synthesize triglycerides. As a result, some degree of dedifferentiation of adipocytes to preadipocyte-like cells is achieved. These changes may be involved in the reduction in fat depots and in the improvement of insulin sensitivity observed after bezafibrate treatment.Keywords
This publication has 42 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- Uncoupling Protein-3 mRNA Levels Are Increased in White Adipose Tissue and Skeletal Muscle of Bezafibrate-Treated RatsBiochemical and Biophysical Research Communications, 1999
- Bezafibrate has an antioxidant effect: Peroxisome proliferator-activated receptor α is associated with Cu2+, Zn2+-superoxide dismutase in the liverLife Sciences, 1998
- Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglyceridesDiabetes, 1997
- The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular AnalysisEuropean Journal of Biochemistry, 1997
- Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult ratEndocrinology, 1996
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994
- Lowering of Plasma Glucose Concentrations With Bezafibrate in Patients With Moderately Controlled NIDDMDiabetes Care, 1990
- Bezafibrate Retard in Type II Diabetic PatientsJournal of Cardiovascular Pharmacology, 1990
- Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and manPharmacology & Therapeutics, 1985